Table 6 Factors associated with BZRA deprescribing: Univariate analysis

 Age

1 [0.9;1]

.080

 Female

1 [0.7;1.4]

.927

 Home

1

 Nursing home

1.5 [1;2.2]

.030

 CIRS-G

1.1 [1;1.1]

.001

 Anxiety

1.3 [0.9;2.1]

.194

 Sleep disorder

1.2 [0.6;2.1]

.636

 Restless leg syndrome

1.1 [0.4;3]

.867

 Depression

1.3 [0.9;2]

.161

 Bipolar or psychotic disorder

1.1 [0.4;3]

.867

 Extrapyramidal syndrome

0.7 [0.4;1.1]

.147

 Previous fracture

1.3 [0.9;1.8]

.201

 Fall at admission

1 [0.7;1.3]

.825

 Current fracture

0.8 [0.5;1.2]

.288

 COPD

1 [0.6;1.7]

.847

 Delirium

1.7 [1.2;2.4]

.009

 Cognitive decline

1.5 [1.1;2.1]

.028

  Direct to AGU

1

  Emergency

1.3 [0.9;2]

.214

  Transfer

1.7 [1;2.9]

.033

Length of stay

1 [1;1]

.126

  Home

1

  Nursing home

1.6 [1.1;2.3]

.007

  Another ward

0.9 [0.5;1.4]

.776

 Total medications

1 [1;1.1]

.218

 Polypharmacy

0.8 [0.4;1.5]

.460

 Excessive polypharmacy

1.3 [1;1.9]

.094

 BZRA dose

1.3 [1.1;1.5]

.003

 Multi-BZRA users

3.3 [2.2;5.2]

<.001

 Psychotropic polpharmacy

2 [1.4;2.8]

<.001

 Antipsychotic users

0.8 [0.5;1.2]

.164

 Antidepressant users

1.8 [1.3;2.5]

.002

  Trazodone

1.8 [1;3]

.033

  Mirtazapine

1.2 [0.7; 2.3]

.483

 Palliative status

1.2 [0.6;2.2]

.630

 Intervention of a clinical pharmacist

1.8 [1.2;2.5]

.003

 Identification of a BZRA-related adverse event by the treating physician

5.1 [3.1;8.6]

<.001

 BZRA switch between admission and discharge

0.9 [0.5; 1.6]

.766